m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05718
|
[1] | |||
m6A modification
GAS5
GAS5
YTHDF2
 : m6A sites
Direct
Inhibition
Non-coding RNA
GAS5
DRP1
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | |||
| m6A Target | Growth arrest specific 5 (GAS5) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | Growth arrest specific 5 (GAS5) | LncRNA | View Details | ||
| Regulated Target | Dynamin-1-like protein (DRP1) | View Details | |||
| Crosstalk Relationship | m6A → ncRNA | Inhibition | |||
| Crosstalk Mechanism | m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA | ||||
| Crosstalk Summary | METTL3 mediated m6A methylation of LncRNA-Growth arrest specific 5 (GAS5) via an YTHDF2-dependent manner. METTL3 boosts mitochondrial fission and induces cardiac fibrosis by enhancing LncRNA GAS5 methylation. Overexpression of GAS5 suppressed Dynamin-1-like protein (DRP1)-mediated mitochondrial fission, inhibiting cardiac fibroblast proliferation and migration. | ||||
| Responsed Disease | Vascular disorders of the liver | ICD-11: DB98.8 | |||
| Cell Process | Cell proliferation | ||||
| Cell migration | |||||
In-vitro Model |
NIH 3T3 | Normal | Mus musculus | CVCL_0594 | |
| In-vivo Model | The in vivo assay was approved by the Animal Care and Use Committee of Anhui Medical University. And all experimental procedures and animal care were in accordance with the institutional ethics guidelines for animal experiments. The C57BL/6 mice (male, 8-10 weeks old) were housed (six per cage) in a specific and opportunistic pathogen-free facility and maintained on a 12-hlight-dark cycle with casually access to food and water. Detailed descriptions of the cell culture, cardiac fibrosis model, and treatment with lentiviral, were given in the Supplementary methods online. | ||||